Business Wire

1 in 2 girls are quitting sport due to periods, according to new global report by PUMA and Modibodi®

2.5.2022 15:00:00 EEST | Business Wire | Press release

Share

As part of the launch of their new leak-proof underwear collection, global sports company PUMA and leak-proof apparel company Modibodi® have commissioned a global survey that investigated the reason girls are leaving sport; shining a light on the numbers that really matter.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005440/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Global sports company PUMA and leak-proof apparel company Modibodi® have commissioned a global survey that investigated the reason girls are leaving sport. The statistics unearthed were shocking, with 1 in 2 teens skipping sport because of their period. (Photo: Business Wire)

Sport is all about numbers. And when it comes to the celebration of sport, the goals kicked, and games won are the numbers that take centre stage. But there’s series of numbers that are less well-known: the number of girls leaving sport daily, due to shame and fear of leaks.

The statistics unearthed were shocking, with 1 in 2 teens skipping sport because of their period. The PUMA and Modibodi® global survey discovered that for many girls, sport stops because of embarrassment, pain or fear of leaks during their period. The survey insights show how the culture and lack of innovation around periods is holding girls back from participating in sport. The discomfort of disposable products coupled, from a coaching perspective, with a lack of education and training, has meant that the result is female players finding the fear of leaking psychologically impacting their sporting performance.

With the subject of periods going undiscussed in the sports world, Australian PUMA athlete and AFL Collingwood star, Sabrina Frederick, is keen to break the stigma: “I was one of the ones who stayed in sport. But for many girls, that’s not a reality. Periods shouldn’t stop young girls from participating in sport. These are numbers we need to address, to keep girls in sport longer.”

Ali Riley, New Zealand PUMA athlete and captain of the Football Ferns, says “It's time to break the silence and help women and girls stay comfortable and active during their period. What’s fantastic about the PUMA x Modibodi active underwear collection is that it has been designed specifically to help making playing sport on your period more possible than ever before.”

The PUMA x Modibodi collection replaces the need for disposable pads, liners and tampons as you play. Modibodi’s proprietary Modifier Technology™ wicks moisture and sweat, locks away fluid and odour and keeps you feeling fresh and dry, without the discomfort of disposables.

“3 in 5 teens skip sport due to fear of leaking or revealing their period which is why we are thrilled to launch this collection with PUMA and together normalize menstruation and tackle the stigma that women can't be active on their periods or when experiencing any of life’s leaks.” said Kristy Chong, CEO and Founder, Modibodi

“Our data also shows that 1 in 2 experience discomfort from disposable menstrual products like pads and tampons when participating in sport or physical exercise- so by releasing this range of leak-proof underwear we are hoping to make playing sport on your period more comfortable, more protected, and more possible than ever. Changing the world should be as easy as changing your underwear. Waste-free, leak-free, worry-free protection.”

Under the “She Moves Us” platform, PUMA together with Modibodi believe that everybody who wants to participate in exercise or sport should be given the opportunity to stay active and play.

“3 in 4 women believe periods need to be more openly discussed in the sports world and it’s why we are proud to partner with Modibodi to shine a light on these numbers that really matter in sports.” said Erin Longin, Global Director Running and Training business unit at PUMA. “As a global brand, we felt it important to do our part to address this issue.”

As part of the launch, PUMA and Modibodi will work with PUMA’s She Moves Us charity partner, Women Win, to donate bundle packs to 500 girls and women in need. “Period poverty is a huge issue globally but one that isn’t nearly spoken about enough. Making sustainable menstrual products widely available is something that needs to be addressed urgently and that is why I am so proud to be a part of the PUMA x Modibodi collaboration”, says Jodie Williams, British sprinter and PUMA athlete.

The PUMA x Modibodi collection consists of 3 styles of active underwear: thong, brief and boyshort, designed to suit every body. Each style is available in two colour ways: dark slate and grape wine and to maximise comfort whilst playing sports, includes a unique, 3mm thin gusset with Modibodi’s scientifically proven absorbent Modifier Technology ™.

With a wider waist band to ensure security whilst playing and aerated side panels designed for comfort and to maximise airflow, the PUMA x Modibodi active underwear range offers women and girls the ability to stay active without having to worry about leaks, while reducing their monthly waste from period products.

The PUMA x Modibodi active underwear collection is available in selected stores and online at modibodi.com and puma.com

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 70 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 14,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

MODIBODI

Founded in 2013, Modibodi® is Australia’s original leak-proof apparel brand, designing underwear, swimwear, active wear, maternity wear and reusable nappies to replace disposable hygiene products and offer a sustainable solution to manage periods, incontinence, discharge, breast milk leaks, sweat and more. Modibodi is warm, authentic and human. We help people with all kinds of leaky bodies get on with their lives. We’re plain speaking and taboo breaking. We’re comfortable in our own skin and not embarrassed to talk about leaky bodies – because they’re part of life. We offer a range of products and sizes across our three brands: Modibodi®, Modibodi RED for tweens and teens, and Modibodi Men to manage incontinence, sweat and chafing. Our Modibodi leak-proof products have been scientifically tested and proven to absorb fluid, resist odour, and keep you dry, thanks to the brand’s patented technology which keeps you feeling comfortable and confident and reduces the impact on the environment. Modibodi is committed to sustainability and social impact, helping end period poverty and normalising conversations about periods and leaks through education and supporting people in need globally. To date, Modibodi has sold millions of garments worldwide, saving billions of single-use disposable hygiene products such as pads, liners and tampons from ending up in landfill.

Changing the world should be as easy as changing your underwear. Waste-free, leak-free, worry- free protection.

Source: PUMA and Modibodi® Global Survey into Girls Leaving Sport

Survey of 1000 girls and women globally, focusing the impact periods have on their relationship to sport, it psychologically impacts on performance as well as the degrees of support received from coaches, schools' education and physical product technology.

Countries: Australia, New Zealand, USA, UK, Europe

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:

PUMA
Gudrun Cäemmerer
Teamhead Global PR
gudrun.caemmerer@puma.com
Phone +49 173 2199376

Modibodi
Lucy Lamming
PR & Partnerships Lead
lucylamming@modibodi.com
Phone +61 403 562 993

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye